Literature DB >> 30042144

Significant gynecological bleeding in women with low von Willebrand factor levels.

Michelle Lavin1,2, Sonia Aguila2, Niall Dalton2, Margaret Nolan1, Mary Byrne1, Kevin Ryan1, Barry White1, Niamh M O'Connell1, Jamie M O'Sullivan2, Jorge Di Paola3, Paula D James4, James S O'Donnell1,2.   

Abstract

Gynecological bleeding is frequently reported in women with von Willebrand disease (VWD). Low von Willebrand factor (VWF) may be associated with significant bleeding phenotype despite only mild plasma VWF reductions. The contribution of gynecological bleeding to this phenotype has yet to be described. The optimal clinical bleeding assessment tool (BAT) to evaluate bleeding remains unclear. Using a standardized approach to phenotypic assessment, we evaluated gynecological bleeding and directly compared the Condensed Molecular and Clinical Markers for the Diagnosis and Management of type 1 VWD (Condensed MCMDM-1 VWD) and International Society on Thrombosis and Haemostasis (ISTH) BAT scores in 120 women enrolled in the Low von Willebrand in Ireland Cohort study. Heavy menstrual bleeding (HMB) was reported in 89% of female participants; 45.8% developed iron deficiency. Using identical data, Condensed MCMDM-1 VWD menorrhagia domain scores were significantly lower than ISTH BAT scores (2 vs 3; P < .0001), the discrepant results related to 40% of women not seeking medical consultation for HMB, reducing the sensitivity of the Condensed score. For those who reported HMB to physicians, the low VWF diagnosis was not expedited (age at diagnosis 34.2 vs 33.4 years in women failing to present; P = .7). Postpartum hemorrhage (PPH) was self-reported in 63.5% of parous women (n = 74); 21.6% required transfusion, critical care, radiological, or surgical intervention. Our data demonstrate that gynecological bleeding is frequently reported in women with low VWF; despite pregnancy-related increases in plasma VWF levels, these women may experience PPH. Defining the optimal management approach for these patients requires further research. This trial was registered at www.clinicaltrials.gov as #NCT03167320.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30042144      PMCID: PMC6058240          DOI: 10.1182/bloodadvances.2018017418

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  31 in total

1.  Postpartum haemorrhage in women with von Willebrand disease: an observational study of the Pennsylvania Health Care Cost Containment Council (PHC4) database.

Authors:  L M Malec; C G Moore; J Yabes; J Li; M V Ragni
Journal:  Haemophilia       Date:  2015-07-20       Impact factor: 4.287

Review 2.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

3.  Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders.

Authors:  R A Kadir; D L Economides; C A Sabin; D Pollard; C A Lee
Journal:  Haemophilia       Date:  1999-01       Impact factor: 4.287

4.  von Willebrand disease and bleeding in women.

Authors:  M V Ragni; F A Bontempo; A C Hassett
Journal:  Haemophilia       Date:  1999-09       Impact factor: 4.287

5.  Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis.

Authors:  A H James; B A Konkle; P Kouides; M V Ragni; B Thames; S Gupta; S Sood; S K Fletcher; C S Philipp
Journal:  Haemophilia       Date:  2014-10-21       Impact factor: 4.287

Review 6.  von Willebrand's disease and menorrhagia: prevalence, diagnosis, and management.

Authors:  Jody L Kujovich
Journal:  Am J Hematol       Date:  2005-07       Impact factor: 10.047

7.  Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation.

Authors:  Claire S Philipp; Ambarina Faiz; Nicole F Dowling; Michele Beckman; Sally Owens; Charletta Ayers; Gloria Bachmann
Journal:  Am J Obstet Gynecol       Date:  2008-02       Impact factor: 8.661

8.  von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).

Authors:  W L Nichols; M B Hultin; A H James; M J Manco-Johnson; R R Montgomery; T L Ortel; M E Rick; J E Sadler; M Weinstein; B P Yawn
Journal:  Haemophilia       Date:  2008-03       Impact factor: 4.287

9.  Obstetric management in von Willebrand's disease: a report of 24 pregnancies and a reivesw of the literature.

Authors:  B H Ramsahoye; S V Davies; H Dasani; J F Pearson
Journal:  Haemophilia       Date:  1995-04       Impact factor: 4.287

Review 10.  The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.

Authors:  Mike A Laffan; Will Lester; James S O'Donnell; Andrew Will; Robert Campbell Tait; Anne Goodeve; Carolyn M Millar; David M Keeling
Journal:  Br J Haematol       Date:  2014-08-12       Impact factor: 6.998

View more
  21 in total

Review 1.  Haemostatic disorders in pregnancy.

Authors:  R Agarwala; C M Millar; J P Campbell
Journal:  BJA Educ       Date:  2020-03-18

2.  Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation.

Authors:  Judicael Fazavana; Teresa M Brophy; Alain Chion; Niamh Cooke; Virginie Terraube; Justin Cohen; Chuenlei Parng; Debra Pittman; Orla Cunningham; Matthew Lambert; James S O'Donnell; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

3.  New advances in the diagnosis of von Willebrand disease.

Authors:  Ruchika Sharma; Sandra L Haberichter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

4.  ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.

Authors:  Nathan T Connell; Veronica H Flood; Romina Brignardello-Petersen; Rezan Abdul-Kadir; Alice Arapshian; Susie Couper; Jean M Grow; Peter Kouides; Michael Laffan; Michelle Lavin; Frank W G Leebeek; Sarah H O'Brien; Margareth C Ozelo; Alberto Tosetto; Angela C Weyand; Paula D James; Mohamad A Kalot; Nedaa Husainat; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

5.  Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the hematologist's view.

Authors:  Margaret V Ragni
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 6.  Women and bleeding disorders: diagnostic challenges.

Authors:  Paula D James
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 7.  New developments in von Willebrand disease.

Authors:  Helen Fogarty; Dearbhla Doherty; James S O'Donnell
Journal:  Br J Haematol       Date:  2020-05-12       Impact factor: 6.998

8.  von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.

Authors:  Ferdows Atiq; Lisette M Schütte; Agnes E M Looijen; Johan Boender; Marjon H Cnossen; Jeroen Eikenboom; Moniek P M de Maat; Marieke J H A Kruip; Frank W G Leebeek
Journal:  Blood Adv       Date:  2019-12-23

Review 9.  Low VWF: insights into pathogenesis, diagnosis, and clinical management.

Authors:  James S O'Donnell
Journal:  Blood Adv       Date:  2020-07-14

Review 10.  The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.

Authors:  Soracha E Ward; Jamie M O'Sullivan; James S O'Donnell
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.